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pTATE-OF-THE-ART PAPER1829Percutaneous Aortic Valve Replacementlan Zajarias, Alain G. Cribier
ajarias and Cribier review the use of transcatheter aortic valve replacement as an option for
atients with severe symptomatic aortic stenosis. Early problems regarding valve sizing, valve
ositioning, and patient selection are being addressed. Technological improvements have
llowed the use of smaller arterial sheaths and special catheters to facilitate valve delivery.
idterm follow-up of patients who have undergone the procedure shows no evidence of
rosthetic valve dysfunction. Randomized trials that are currently underway will confirm
rocedural safety and guide the applicability of this technology.TATE-OF-THE-ART PAPER1837Percutaneous Mitral and Pulmonary Valve Therapiesicolo Piazza, Anita Asgar, Reda Ibrahim, Raoul Bonan
iazza and colleagues review the state of the art for the percutaneous treatment of mitral and
ulmonary valve disorders. Although numerous milestones and advancements have already
een achieved, transcatheter valve therapy is still considered to be in its infancy. It remains
nclear whether the optimal therapy for mitral regurgitation will be the clipping of the mitral
alve leaflet to create a double orifice or modification of the mitral annulus. Several techniques
or percutaneous repair of pulmonary valves are also reviewed.IEWPOINT1852Antibiotic Prophylaxis for Infective Endocarditis Should Be Personalizedavid S. Bach
n a viewpoint article, Bach discusses the recent changes made in the American Heart
ssociation and American College of Cardiology Guidelines for the Management of Patients
ith Valvular Heart Disease regarding the use of antibiotic prophylaxis in patients at risk of
nfective endocarditis. The new recommendations represent a dramatic decrease in both the
umber of patients and the procedures for which antibiotic prophylaxis is recommended.
ach laments that this dramatic shift in recommendations is based not on new data, but on
o data. Bach argues that the risk of antibiotic prophylaxis is negligible in most patients, and
herefore, until new data becomes available, the decision should be personalized for each
atient.(continued on page A-22)
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fLINICAL RESEARCH1855Initial Experience With a New Percutaneous Aortic Valve Delivery Systemohn G. Webb, Lukas Altwegg, Jean-Bernard Masson, Saad Al Bugami, Abdullah Al Ali, Robert A. Boone
nitial attempts at percutaneous aortic valve replacement were compromised by the difficulties
ncountered with vascular passage of a relatively bulky prosthetic valve compressed onto a
emi-rigid valvuloplasty catheter. In this paper, Webb and colleagues describe their experience
n 25 high-risk patients with a next-generation delivery catheter system and current-
eneration percutaneous aortic valves. The procedure was technically acceptable in all 25
atients with no deaths through the 30-day follow-up; the aortic valve area increased from
.59 to 1.60 cm2. Technical advances in catheter systems and prosthetic valves designed for
ercutaneous delivery may lead to improved procedural success.LINICAL RESEARCH
1859ercutaneous Placement of a Pulmonary
Valve in Patients With Repaired Tetralogy of Fallotarek S. Momenah, Reida El Oakley, Khalid Al Najashi, Saad Khoshhal, Howaida Al Qethamy,
hilipp Bonhoeffer
urrent indications for percutaneous pulmonary valve implantation (PPVI) are limited to
atients who have pulmonary valve stenosis and/or regurgitation in a right ventricle to
ulmonary artery conduit, but exclude patients with right ventricular outflow tract (RVOT)
atch. Momenah and colleagues describe their experience in 13 patients. The diameter and
istensibility of the RVOT patch were assessed by inflation of a balloon; a stent was then
laced to serve as an anchor for the valve. A Melody valve (Medtronic Inc.) was then
ntroduced and inflated, which resulted in improved hemodynamics by both right heart
atheterization and echocardiography. There were no obvious complications in the short-term
ollow-up. PPVI with pre-stenting may be a viable treatment for pulmonary regurgitation
ollowing RVOT patching.(continued on page A-23)
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rLINICAL RESEARCH1865Outcomes of Patients With LF/LGAS Without Contractile Reserve CMEhristophe Tribouilloy, Franck Lévy, Dan Rusinaru, Pascal Guéret, Hélène Petit-Eisenmann,
erge Baleynaud, Yannick Jobic, Catherine Adams, Bernard Lelong, Agnès Pasquet, Christophe Chauvel,
amien Metz, Jean-Paul Quéré, Jean-Luc Monin
he operative mortality in patients with low-flow/low-gradient aortic stenosis (LF/LGAS)
ho do not have contractile reserve (CR) with dobutamine infusion is reported to be as high
s 30%. This has led many to recommend conservative rather than surgical management.
ribouilloy and colleagues followed 81 patients without CR, defined as an increase in stroke
olume 20% with dobutamine, and LF/LGAS, defined as valve area 1 cm2, left
entricular ejection fraction 40%, and mean pressure gradient 40 mm Hg. The decision
or surgery was left to the treating physicians. The 5-year survival was higher in operated
atients compared with medically-managed patients (55% vs. 14%) despite an operative
ortality of 22%. The mortality in patients with LF/LGAS without CR managed medicallys extraordinarily high and can be improved with surgery in select patients.LINICAL RESEARCH1874Statins May Delay the Progression of Rheumatic ASEditorial Comment
Ori Ben-Yehuda, Anthony N. DeMaria,rancesco Antonini-Canterin, Elisa Leiballi, Roxana Enache, Bogdan A. Popescu, Monica Ros¸ca,
ugenio Cervesato, Rita Piazza, Carmen Ginghina˘, Gian Luigi Nicolosi
he hypothesis that hydroxymethylglutaryl coenzyme-A reductase inhibitor (statin) treatment
ould slow the progression of degenerative aortic valve stenosis (AS) is still controversial.
ntonini-Canterin and colleagues assessed the effect of statin treatment on the progression of
S in patients with rheumatic heart disease. Patients with a history of rheumatic AS with at
east 2 echocardiographic studies 2 years apart were included in a retrospective analysis.
rogression of AS severity was slower in patients receiving statins; an annual rate of peak
elocity progression 0.1 m/s was found in 10% of statin users compared with 49% of
onusers. This is the first observation of a positive effect of statin treatment in reducing the
rogression of rheumatic AS.LINICAL RESEARCH
1883ercutaneously Implanted Aortic Bioprostheses Have
Lower Transvalvular Gradients Than Surgically Implanted ValvesEditorial Comment
Thomas Walther, Volkmar Falk,arie-Annick Clavel, John G. Webb, Philippe Pibarot, Lukas Altwegg, Eric Dumont, Chris Thompson,
obert De Larochellière, Daniel Doyle, Jean-Bernard Masson, Sebastien Bergeron, Olivier F. Bertrand,
osep Rodés-Cabau
lavel and colleagues compared the hemodynamic performance of a percutaneously implanted
alve with that of a surgically implanted bioprosthesis for the treatment of aortic stenosis.
atients who underwent percutaneous aortic valve implantation (PAVI) were matched with
atients who underwent surgical aortic valve replacement (SAVR) with a stented (ST) or a
tentless (SL) valve. Mean transprosthetic gradient at discharge was lower in the PAVI group
ompared with the SAVR-ST and SAVR-SL groups. Aortic regurgitation occurred more
requently in the PAVI group but was usually mild. The incidence of severe prosthesis-patient
ismatch was significantly lower in the PAVI group. This study suggests that PAVI may
esult in a larger effective orifice area than SAVR.
(continued on page A-28)
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iEAR IN CARDIOLOGY SERIES1894The Year in Valvular Heart Diseasehahbudin H. Rahimtoola
ahimtoola reviews the literature for the past year to identify articles that address the broad
eld of valvular heart disease and that will have the biggest impact on the field. In an outline
orm, the articles are clearly summarized with the implications, and sometimes the limitations,
lainly identified.PEDIATRIC CARDIOLOGY EDIATRIC CARDIOLOGY
1909olymorphisms in RAAS Pathway Genes
Increase Risk of Cardiac Transplant Rejectioncott R. Auerbach, Cedric Manlhiot, Sushma Reddy, Caroline Kinnear, Marc E. Richmond, Dorota Gruber,
rian W. McCrindle, Liyong Deng, Jonathan M. Chen, Linda J. Addonizio, Wendy K. Chung, Seema Mital
uerbach and colleagues investigated the influence of recipient renin-angiotensin-aldosterone
ystem (RAAS) genotype on cardiac function, rejection, and outcomes after heart transplant
n pediatric patients. A total of 145 patients 25 years of age, post-cardiac transplant, were
nrolled and genotyped for polymorphisms in genes associated with RAAS up-regulation.
he number of homozygous high-risk RAAS polymorphisms predicted the risk of graft
ysfunction and death. Further studies will determine if RAAS inhibitors improve outcomes
n these patients.
